GPX4 and neoplasm: Targeted inhibition of LCN2 by anti-LCN2 monoclonal antibody (3D12B2) increases intracellular iron levels, decreases GPX4 expression, and induces ferroptosis in tumor cells, thereby overcoming resistance (Chaudhary et al., 2021) (Table 3).